AG˹ٷ

STOCK TITAN

[Form 4] Amarin Corp Plc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

This Form 4 reports routine equity activity by Amarin Corp. (AMRN) SVP & CFO Peter L. Fishman on 1 Aug 2025 following the 1-for-20 ADS ratio adjustment implemented 11 Apr 2025. Fishman acquired 312 American Depositary Shares (ADS) upon the partial vesting of 2022-granted RSUs (transaction code M). To cover withholding taxes, the company retained 160 ADS at an imputed price of $14.52 (code F). After the net settlement, Fishman’s direct holding stands at 3,988 ADS (�79,760 ordinary shares).

The RSU grant originally comprised 1,250 units vesting in four equal tranches from 2023-2026; the 2025 installment is reflected here. No open-market buying or selling occurred, and no derivative positions were closed or written. The filing signals continued insider ownership but is operationally neutral with no implications for Amarin’s fundamentals or guidance.

Questo modulo 4 riporta un'attività azionaria ordinaria da parte di Peter L. Fishman, SVP e CFO di Amarin Corp. (AMRN), avvenuta il 1° agosto 2025, a seguito dell'aggiustamento del rapporto ADS 1-per-20 implementato l'11 aprile 2025. Fishman ha acquisito 312 American Depositary Shares (ADS) in seguito al parziale maturare delle RSU concesse nel 2022 (codice transazione M). Per coprire le tasse trattenute, la società ha trattenuto 160 ADS a un prezzo imputato di $14,52 (codice F). Dopo il regolamento netto, la detenzione diretta di Fishman è di 3.988 ADS (circa 79.760 azioni ordinarie).

La concessione di RSU comprendeva originariamente 1.250 unità con maturazione in quattro tranche uguali dal 2023 al 2026; qui è riflessa la tranche del 2025. Non si sono verificate compravendite sul mercato aperto né chiusure o emissioni di posizioni derivati. La comunicazione indica una continuità nella proprietà interna ma è operativamente neutra, senza implicazioni per i fondamentali o le previsioni di Amarin.

Este Formulario 4 informa sobre una actividad rutinaria de acciones por parte de Peter L. Fishman, SVP y CFO de Amarin Corp. (AMRN) el 1 de agosto de 2025, tras el ajuste de la proporción ADS 1 a 20 implementado el 11 de abril de 2025. Fishman adquirió 312 American Depositary Shares (ADS) tras el otorgamiento parcial de RSU concedidas en 2022 (código de transacción M). Para cubrir impuestos retenidos, la compañía retuvo 160 ADS a un precio imputado de $14.52 (código F). Después del asentamiento neto, la tenencia directa de Fishman es de 3,988 ADS (aproximadamente 79,760 acciones ordinarias).

La concesión de RSU originalmente comprendía 1,250 unidades con vesting en cuatro partes iguales desde 2023 hasta 2026; aquí se refleja la parte correspondiente a 2025. No hubo compras o ventas en el mercado abierto, ni cierre o emisión de posiciones derivadas. La presentación indica una propiedad interna continua, pero es operativamente neutral, sin implicaciones para los fundamentos o las proyecciones de Amarin.

� Form 4� Amarin Corp.(AMRN)� SVP � CFO� Peter L. Fishman� 2025� 8� 1일에 보고� 일상적인 주식 거래 내역� 나타냅니�. 이는 2025� 4� 11일에 시행� 1대 20 ADS 비율 조정 이후� 내용입니�. Fishman은 2022년에 부여된 RSU� 일부 베스팅으� 312개의 미국예탁증서(ADS)� 취득했습니다(거래 코드 M). 원천징수세를 충당하기 위해 회사� 160 ADS� $14.52� 가� 가격으� 보유했습니다(코드 F). 순결� � Fishman� 직접 보유 주식 수는 3,988 ADS(� 79,760 보통�)입니�.

RSU 부여는 원래 2023년부� 2026년까지 4회에 걸쳐 균등하게 베스팅되� 1,250 단위� 구성되었으며, 여기에는 2025� 분할� 반영되어 있습니다. 공개 시장에서� 매매� 파생상품 포지션의 청산 또는 신규 설정은 없었습니�. 이번 신고� 내부� 보유가 계속됨을 나타내지�, Amarin� 기본� 상황이나 가이던스에� 운영� 중립�� 의미� 가집니�.

Ce formulaire 4 rapporte une activité courante sur actions par Peter L. Fishman, SVP et CFO d'Amarin Corp. (AMRN), le 1er août 2025, suite à l'ajustement du ratio ADS 1 pour 20 mis en place le 11 avril 2025. Fishman a acquis 312 American Depositary Shares (ADS) lors de la levée partielle des RSU attribuées en 2022 (code transaction M). Pour couvrir les impôts retenus à la source, la société a retenu 160 ADS à un prix imputé de 14,52 $ (code F). Après le règlement net, la détention directe de Fishman s'élève à 3 988 ADS (environ 79 760 actions ordinaires).

La subvention initiale de RSU comprenait 1 250 unités vestant en quatre tranches égales de 2023 à 2026 ; la tranche de 2025 est reflétée ici. Aucun achat ou vente sur le marché ouvert n'a eu lieu, et aucune position dérivée n'a été clôturée ou émise. Le dépôt indique une propriété continue des initiés mais est opérationnellement neutre, sans incidence sur les fondamentaux ou les prévisions d'Amarin.

Dieses Formular 4 berichtet über routinemäßige Aktienaktivitäten von Peter L. Fishman, SVP & CFO von Amarin Corp. (AMRN), am 1. August 2025 nach der Umsetzung der 1-zu-20 ADS-Verhältnis-Anpassung am 11. April 2025. Fishman erwarb 312 American Depositary Shares (ADS) im Rahmen der teilweisen Vesting der 2022 gewährten RSUs (Transaktionscode M). Zur Deckung der Quellensteuer behielt das Unternehmen 160 ADS zu einem fiktiven Preis von $14,52 ein (Code F). Nach der Nettoregelung hält Fishman direkt 3.988 ADS (ca. 79.760 Stammaktien).

Der RSU-Zuschuss umfasste ursprünglich 1.250 Einheiten, die in vier gleichen Tranchen von 2023 bis 2026 vesten; hier ist die Tranche von 2025 dargestellt. Es gab keinen Kauf oder Verkauf am offenen Markt und keine Schließung oder Ausgabe von Derivatpositionen. Die Meldung signalisiert eine fortgesetzte Insiderbeteiligung, ist jedoch operativ neutral und hat keine Auswirkungen auf die Fundamentaldaten oder Prognosen von Amarin.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; CFO nets +152 ADS, retains 3,988—no market signal.

The filing shows standard annual vesting under the 2011 Stock Incentive Plan. The CFO took delivery of 312 ADS and surrendered 160 ADS for taxes at a fair-market value of $14.52, leaving a modest net increase in ownership. No discretionary sale occurred, so the transaction does not reflect a view on valuation. With total holdings under $60 k, material impact on float or sentiment is negligible. I classify the disclosure as not impactful and neutral for investors.

Questo modulo 4 riporta un'attività azionaria ordinaria da parte di Peter L. Fishman, SVP e CFO di Amarin Corp. (AMRN), avvenuta il 1° agosto 2025, a seguito dell'aggiustamento del rapporto ADS 1-per-20 implementato l'11 aprile 2025. Fishman ha acquisito 312 American Depositary Shares (ADS) in seguito al parziale maturare delle RSU concesse nel 2022 (codice transazione M). Per coprire le tasse trattenute, la società ha trattenuto 160 ADS a un prezzo imputato di $14,52 (codice F). Dopo il regolamento netto, la detenzione diretta di Fishman è di 3.988 ADS (circa 79.760 azioni ordinarie).

La concessione di RSU comprendeva originariamente 1.250 unità con maturazione in quattro tranche uguali dal 2023 al 2026; qui è riflessa la tranche del 2025. Non si sono verificate compravendite sul mercato aperto né chiusure o emissioni di posizioni derivati. La comunicazione indica una continuità nella proprietà interna ma è operativamente neutra, senza implicazioni per i fondamentali o le previsioni di Amarin.

Este Formulario 4 informa sobre una actividad rutinaria de acciones por parte de Peter L. Fishman, SVP y CFO de Amarin Corp. (AMRN) el 1 de agosto de 2025, tras el ajuste de la proporción ADS 1 a 20 implementado el 11 de abril de 2025. Fishman adquirió 312 American Depositary Shares (ADS) tras el otorgamiento parcial de RSU concedidas en 2022 (código de transacción M). Para cubrir impuestos retenidos, la compañía retuvo 160 ADS a un precio imputado de $14.52 (código F). Después del asentamiento neto, la tenencia directa de Fishman es de 3,988 ADS (aproximadamente 79,760 acciones ordinarias).

La concesión de RSU originalmente comprendía 1,250 unidades con vesting en cuatro partes iguales desde 2023 hasta 2026; aquí se refleja la parte correspondiente a 2025. No hubo compras o ventas en el mercado abierto, ni cierre o emisión de posiciones derivadas. La presentación indica una propiedad interna continua, pero es operativamente neutral, sin implicaciones para los fundamentos o las proyecciones de Amarin.

� Form 4� Amarin Corp.(AMRN)� SVP � CFO� Peter L. Fishman� 2025� 8� 1일에 보고� 일상적인 주식 거래 내역� 나타냅니�. 이는 2025� 4� 11일에 시행� 1대 20 ADS 비율 조정 이후� 내용입니�. Fishman은 2022년에 부여된 RSU� 일부 베스팅으� 312개의 미국예탁증서(ADS)� 취득했습니다(거래 코드 M). 원천징수세를 충당하기 위해 회사� 160 ADS� $14.52� 가� 가격으� 보유했습니다(코드 F). 순결� � Fishman� 직접 보유 주식 수는 3,988 ADS(� 79,760 보통�)입니�.

RSU 부여는 원래 2023년부� 2026년까지 4회에 걸쳐 균등하게 베스팅되� 1,250 단위� 구성되었으며, 여기에는 2025� 분할� 반영되어 있습니다. 공개 시장에서� 매매� 파생상품 포지션의 청산 또는 신규 설정은 없었습니�. 이번 신고� 내부� 보유가 계속됨을 나타내지�, Amarin� 기본� 상황이나 가이던스에� 운영� 중립�� 의미� 가집니�.

Ce formulaire 4 rapporte une activité courante sur actions par Peter L. Fishman, SVP et CFO d'Amarin Corp. (AMRN), le 1er août 2025, suite à l'ajustement du ratio ADS 1 pour 20 mis en place le 11 avril 2025. Fishman a acquis 312 American Depositary Shares (ADS) lors de la levée partielle des RSU attribuées en 2022 (code transaction M). Pour couvrir les impôts retenus à la source, la société a retenu 160 ADS à un prix imputé de 14,52 $ (code F). Après le règlement net, la détention directe de Fishman s'élève à 3 988 ADS (environ 79 760 actions ordinaires).

La subvention initiale de RSU comprenait 1 250 unités vestant en quatre tranches égales de 2023 à 2026 ; la tranche de 2025 est reflétée ici. Aucun achat ou vente sur le marché ouvert n'a eu lieu, et aucune position dérivée n'a été clôturée ou émise. Le dépôt indique une propriété continue des initiés mais est opérationnellement neutre, sans incidence sur les fondamentaux ou les prévisions d'Amarin.

Dieses Formular 4 berichtet über routinemäßige Aktienaktivitäten von Peter L. Fishman, SVP & CFO von Amarin Corp. (AMRN), am 1. August 2025 nach der Umsetzung der 1-zu-20 ADS-Verhältnis-Anpassung am 11. April 2025. Fishman erwarb 312 American Depositary Shares (ADS) im Rahmen der teilweisen Vesting der 2022 gewährten RSUs (Transaktionscode M). Zur Deckung der Quellensteuer behielt das Unternehmen 160 ADS zu einem fiktiven Preis von $14,52 ein (Code F). Nach der Nettoregelung hält Fishman direkt 3.988 ADS (ca. 79.760 Stammaktien).

Der RSU-Zuschuss umfasste ursprünglich 1.250 Einheiten, die in vier gleichen Tranchen von 2023 bis 2026 vesten; hier ist die Tranche von 2025 dargestellt. Es gab keinen Kauf oder Verkauf am offenen Markt und keine Schließung oder Ausgabe von Derivatpositionen. Die Meldung signalisiert eine fortgesetzte Insiderbeteiligung, ist jedoch operativ neutral und hat keine Auswirkungen auf die Fundamentaldaten oder Prognosen von Amarin.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fishman Peter L.

(Last) (First) (Middle)
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AMARIN CORP PLC\UK [ AMRN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CFO
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Share(1) 08/01/2025 M(2) 312(1) A (3) 4,148(1) D
American Depositary Share(1) 08/01/2025 F(4) 160(1) D $14.52 3,988(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit(5) $0.00 08/01/2025 A 312(1) (2) (3) American Depositary Shares(1) 312(1) $0.00 313(1) D
Explanation of Responses:
1. Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
2. On August 8, 2022, the Reporting Person was granted 1,250 RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in four equal installments on each of August 1, 2023, August 1, 2024, August 1, 2025, and August 1, 2026.
3. Not applicable.
4. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
5. Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
/s/ Jonathan Provoost, by power of attorney 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AMRN ADS does CFO Peter Fishman own after the 1 August 2025 transaction?

He directly owns 3,988 American Depositary Shares after net settlement.

What type of insider transaction was disclosed in the AMRN Form 4?

It reflects RSU vesting (code M) and withholding for taxes (code F); no open-market sale or purchase.

At what price were ADS withheld for taxes in the AMRN Form 4 filing?

Shares were withheld at an imputed value of $14.52 per ADS.

Why did the share counts change after Amarin’s ADS ratio adjustment?

On 11 Apr 2025, Amarin changed its ADS ratio to 1 ADS = 20 ordinary shares; all equity awards, including RSUs, were proportionally adjusted.

Does the Form 4 signal any change in Amarin’s financial outlook?

No. The filing is a routine equity compensation event and does not affect guidance or fundamentals.
Amarin

NASDAQ:AMRN

AMRN Rankings

AMRN Latest News

AMRN Latest SEC Filings

AMRN Stock Data

319.96M
20.49M
1.88%
18.89%
2.3%
Drug Manufacturers - General
Pharmaceutical Preparations
Ireland
DUBLIN 2